# TNAX Biopharma Corporation

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tnax-biopharma

- Industry: Biotechnology
- Headquarters: Tsukuba, Japan
- Website: https://tnaxbio.com
- Total disclosed funding: $4.4M
- Latest round: Series A (Nov 30, 2018)
- Investors on record: 3

## About

TNAX Biopharma Corporation develops innovative antibody therapeutics targeting unmet medical needs for patients with intractable diseases, focusing on conditions like acute kidney injury and ischemic stroke.Founded in 2018, TNAX Biopharma Corporation is based in Tsukuba, Japan, and specializes in developing antibody therapeutics. The company raised JPY 500 million in its Series A funding round on November 30, 2018, with investments from Mitsubishi UFJ Capital, JAFCO Group, and Nissay Capital, leading to a current company valuation of JPY 911.059 mn.TNAX Biopharma Corporation specializes in the development and commercialization of innovative antibody therapeutics aimed at addressing significant unmet medical needs in patients suffering from intractable diseases. The company's core product offerings are centered around novel antibodies targeting conditions such as cardiac surgery-associated acute kidney injury (CSA-AKI) and acute ischemic stroke (AIS). These therapeutics are designed to mitigate the serious complications arising from procedures like coronary artery bypass grafting (CABG) and to address the ischemia-reperfusion injury associated with recanalization therapy for AIS. TNAX Biopharma collaborates closely with the University of Tsukuba, leveraging exclusive intellectual property rights for their therapeutic development. The geographical markets for these products primarily encompass the United States and Europe, focusing on hospitals and healthcare systems that perform CABG procedures and treat stroke patients.TNAX Biopharma's revenue generation strategy includes partnerships with healthcare institutions and potential pharmaceutical collaborators. The company engages in B2B transactions, aiming to supply hospitals and healthcare providers with its therapeutic products. These partnerships may involve joint ventures or licensing agreements, allowing for the distribution of their innovative antibody therapeutics. The transaction structure is designed to facilitate bulk procurement by healthcare providers, which can include subscription-based access to new therapies as they become available. Specific pricing plans for TNAX's products have not been disclosed, but the company seeks to align its offerings with the financial frameworks of healthcare systems, ensuring that its therapeutics are accessible for the prevention and treatment of CSA-AKI and AIS in clinical settings.TNAX Biopharma Corporation plans to utilize the JPY 500 million raised in its Series A funding round to advance its product development initiatives and expand into new markets. The firm is focusing on launching new therapeutic products aimed at addressing CSA-AKI and AIS. Future expansion plans include targeting healthcare markets in the United States and Europe by 2025, ensuring that their antibody therapeutics reach a broader patient population.

## Funding rounds

- Series A, Nov 30, 2018, $4.4M — JAFCO Group, Mitsubishi UFJ Capital, Nissay Capital

## Investors

- JAFCO Group (https://capitalatlas.ai/funds/jafco-group) — Series A
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A
- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series A